NCT00436046View on ClinicalTrials.gov

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2007

Study Completion Date

October 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Trivalent inactivated influenza virus vaccine (2006-2007 formulation)

Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.

BIOLOGICAL

Type 1 interferon

Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00436046 - Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally | Biotech Hunter | Biotech Hunter